195 related articles for article (PubMed ID: 36254623)
1. Evaluation of miR-371a-3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection.
Konneh B; Lafin JT; Howard J; Gerald T; Amini A; Savelyeva A; Woldu SL; Lewis CM; Jia L; Margulis V; Coleman N; Scarpini C; Frazier AL; Murray MJ; Amatruda JF; Bagrodia A
Andrology; 2023 May; 11(4):634-640. PubMed ID: 36254623
[TBL] [Abstract][Full Text] [Related]
2. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.
Dieckmann KP; Radtke A; Geczi L; Matthies C; Anheuser P; Eckardt U; Sommer J; Zengerling F; Trenti E; Pichler R; Belz H; Zastrow S; Winter A; Melchior S; Hammel J; Kranz J; Bolten M; Krege S; Haben B; Loidl W; Ruf CG; Heinzelbecker J; Heidenreich A; Cremers JF; Oing C; Hermanns T; Fankhauser CD; Gillessen S; Reichegger H; Cathomas R; Pichler M; Hentrich M; Eredics K; Lorch A; Wülfing C; Peine S; Wosniok W; Bokemeyer C; Belge G
J Clin Oncol; 2019 Jun; 37(16):1412-1423. PubMed ID: 30875280
[TBL] [Abstract][Full Text] [Related]
3. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.
Leão R; van Agthoven T; Figueiredo A; Jewett MAS; Fadaak K; Sweet J; Ahmad AE; Anson-Cartwright L; Chung P; Hansen A; Warde P; Castelo-Branco P; O'Malley M; Bedard PL; Looijenga LHJ; Hamilton RJ
J Urol; 2018 Jul; 200(1):126-135. PubMed ID: 29474847
[TBL] [Abstract][Full Text] [Related]
4. High Expression of microRNA-371a-3p in Cystic Fluid of Post-Chemotherapy Teratoma with Concurrent Normal Serum Levels in Patients with Non-Seminomatous Testicular Germ Cell Tumours.
Dieckmann KP; Hennig F; Anheuser P; Gehrckens R; Viehweger F; Wülfing C; Belge G
Urol Int; 2021; 105(1-2):21-26. PubMed ID: 33049748
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker.
Spiekermann M; Belge G; Winter N; Ikogho R; Balks T; Bullerdiek J; Dieckmann KP
Andrology; 2015 Jan; 3(1):78-84. PubMed ID: 25187505
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of plasma miR-371a-3p in germ cell tumors.
Mego M; van Agthoven T; Gronesova P; Chovanec M; Miskovska V; Mardiak J; Looijenga LHJ
J Cell Mol Med; 2019 Feb; 23(2):1128-1136. PubMed ID: 30536846
[TBL] [Abstract][Full Text] [Related]
7. Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management.
Badia RR; Abe D; Wong D; Singla N; Savelyeva A; Chertack N; Woldu SL; Lotan Y; Mauck R; Ouyang D; Meng X; Lewis CM; Majmudar K; Jia L; Kapur P; Xu L; Frazier AL; Margulis V; Strand DW; Coleman N; Murray MJ; Amatruda JF; Lafin JT; Bagrodia A
J Urol; 2021 Jan; 205(1):137-144. PubMed ID: 32856980
[TBL] [Abstract][Full Text] [Related]
8. Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours.
Dieckmann KP; Radtke A; Spiekermann M; Balks T; Matthies C; Becker P; Ruf C; Oing C; Oechsle K; Bokemeyer C; Hammel J; Melchior S; Wosniok W; Belge G
Eur Urol; 2017 Feb; 71(2):213-220. PubMed ID: 27495845
[TBL] [Abstract][Full Text] [Related]
9. Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for seminoma: Limitations of surgical intervention after first-line chemotherapy.
Tachibana I; Alabd A; Whaley RD; McFadden J; Piroozi A; Hassoun R; Kern SQ; King J; Adra N; Rice KR; Foster RS; Einhorn LH; Cary C; Masterson TA
Urol Oncol; 2023 Sep; 41(9):394.e1-394.e6. PubMed ID: 37543446
[TBL] [Abstract][Full Text] [Related]
10. The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1.
Radtke A; Hennig F; Ikogho R; Hammel J; Anheuser P; Wülfing C; Belge G; Dieckmann KP
Urol Int; 2018; 100(4):470-475. PubMed ID: 29698973
[TBL] [Abstract][Full Text] [Related]
11. Role of postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors.
Nguyen CT; Stephenson AJ
Hematol Oncol Clin North Am; 2011 Jun; 25(3):593-604, ix. PubMed ID: 21570611
[TBL] [Abstract][Full Text] [Related]
12. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
[No Abstract] [Full Text] [Related]
13. Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors.
Nakamura T; Kawauchi A; Oishi M; Ueda T; Shiraishi T; Nakanishi H; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T
Int J Clin Oncol; 2016 Aug; 21(4):791-795. PubMed ID: 26701172
[TBL] [Abstract][Full Text] [Related]
14. Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer.
Lobo J; Leão R; Gillis AJM; van den Berg A; Anson-Cartwright L; Atenafu EG; Kuhathaas K; Chung P; Hansen A; Bedard PL; Jewett MAS; Warde P; O'Malley M; Sweet J; Looijenga LHJ; Hamilton RJ
Eur Urol Oncol; 2021 Jun; 4(3):483-491. PubMed ID: 33288479
[TBL] [Abstract][Full Text] [Related]
15. microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients.
van Agthoven T; Eijkenboom WMH; Looijenga LHJ
Cell Oncol (Dordr); 2017 Aug; 40(4):379-388. PubMed ID: 28612337
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or Nonseminoma.
Seelemeyer F; Pfister D; Pappesch R; Merkelbach-Bruse S; Paffenholz P; Heidenreich A
Eur Urol Oncol; 2024 Jun; 7(3):319-322. PubMed ID: 37932157
[TBL] [Abstract][Full Text] [Related]
17. Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: Evaluation of safety and efficacy.
Nicolai N; Nazzani S; Tesone A; Macchi A; Piva L; Salvioni R; Stagni S; Torelli T; Agostini E; Celso F; Giannatempo P; Procopio G; Avuzzi B; Lanocita R; Cattaneo L; Catanzaro M; Biasoni D
Tumori; 2023 Aug; 109(4):379-386. PubMed ID: 35915559
[TBL] [Abstract][Full Text] [Related]
18. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer.
Syring I; Bartels J; Holdenrieder S; Kristiansen G; Müller SC; Ellinger J
J Urol; 2015 Jan; 193(1):331-7. PubMed ID: 25046619
[TBL] [Abstract][Full Text] [Related]
19. Circulating MicroRNAs, the Next-Generation Serum Biomarkers in Testicular Germ Cell Tumours: A Systematic Review.
Leão R; Albersen M; Looijenga LHJ; Tandstad T; Kollmannsberger C; Murray MJ; Culine S; Coleman N; Belge G; Hamilton RJ; Dieckmann KP
Eur Urol; 2021 Oct; 80(4):456-466. PubMed ID: 34175151
[TBL] [Abstract][Full Text] [Related]
20. A Machine Learning Model to Predict the Histology of Retroperitoneal Lymph Node Dissection Specimens.
Nitta S; Kojima T; Gido M; Nakagawa S; Kakeya H; Kandori S; Kawahara T; Mathis BJ; Kawai K; Negoro H; Nishiyama H
Anticancer Res; 2024 May; 44(5):2151-2157. PubMed ID: 38677742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]